Brief: 60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol
02/05/2024 13:10
May 2 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* 60 DEGREES PHARMACEUTICALS RECEIVES FDA COMMENTS ON
TAFENOQUINE-BABESIOSIS CLINICAL TRIAL PROTOCOL; NO MATERIAL
CHANGES REQUIRED
* 60 DEGREES PHARMACEUTICALS INC: TRIAL PLANNING AND
EXECUTION TO
PROCEED AS PLANNED
* 60 DEGREES PHARMACEUTICALS INC: FDA HAD SOME QUESTIONS AND
RECOMMENDATIONS THAT WILL BE ADDRESSED
* 60 DEGREES PHARMACEUTICALS INC - IS CONTINUING PREPARATORY
ACTIONS TO FACILITATE INITIATION OF PATIENT ENROLLMENT LATER IN
2024
Source text for Eikon: ID:nGNX6Zy0X0
Further company coverage: SXTP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM